巨噬细胞移动因子在骨肉瘤患者血清中的表达及临床意义

[目的]评价巨噬细胞移动因子(MIF)在骨肉瘤患者血清中的表达及临床意义。[方法]应用酶联免疫吸附分析(ELISA)方法,检测30名健康人(对照组)和32例骨肉瘤患者(病例组)初次入院、术后化疗前、术后化疗结束时血清MIF水平,分析MIF的表达与骨肉瘤临床病理特征的关系以及化疗对MIF水平的影响。[结果]病例组患者入院时血清MIF为(1.521±0.520)ng/ml,显著高于对照组的(1.149±0.284)ng/ml(t=3.452,P=0.001)。MIF的血清水平与骨肉瘤临床分期、肿瘤大小和转移存在相关性。患者化疗前血清中MIF水平显著高于化疗后(P<0.05)。[结论]MIF在骨肉瘤患者血清中高表达,可能为骨肉瘤的重要预后因子及潜在的治疗靶点。

Expression of Serum MIF in Patients with Osteosarcoma and its Clinical Significance

[Purpose] To investigate the expression of serum macrophage migration inhibitory factor(MIF) in patients with osteosarcoma and its clinical significance.[Methods] The level of serum MIF of 30 healthy person(control group) and 32 cases with osteosarcoma(case group) at nitial hospitalization,before and after chemotherapy was detected by Enzyme-linked immunosorbent assay(ELISA).The relationship of MIF expression with clinicopathological features of osteosarcoma,and the effect of chemotherapy with the level of serum MIF were analyzed.[Results] The level of serum MIF of case group at nitial hospitalization[(1.521±0.520)ng/ml] was significantly higher than that in control group [(1.149±0284)ng/ml](t=3.452,P=0.001).The level of serum MIF was related to osteosarcoma clinical stages,tumor size and metastasis.The level of serum MIF in patients pre-chemotherapy was significantly higher than that in patients post-chemotherapy.[Conclusion] MIF is high expression in patients with osteosarcoma,it may as a prognostic marker and a potential therapeutic target for osteosarcoma.